Glutamatergic dysfunction linked to energy and membrane lipid metabolism in frontal and anterior cingulate cortices of never treated first-episode schizophrenia patients.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Schizophrenia Research

• Publication date

  2015-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.schres.2015.07.013PMID 26255566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glutamate-mediated excitotoxicity in schizophrenia: a review.

  2014cited by this paper
• Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

  2014cited by this paper
• Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies.

  2013influential reference
• The SLC1 high-affinity glutamate and neutral amino acid transporter family.

  2013cited by this paper
• Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia.

  2013cited by this paper
• Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis.

  2013cited by this paper
• Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study.

  2013cited by this paper
• Synaptic dysfunction in schizophrenia.

  2012cited by this paper
• Glutamatergic animal models of schizophrenia.

  2012cited by this paper
• Glutamatergic transmission in schizophrenia: from basic research to clinical practice

  2012cited by this paper
• Absolute quantitation of brain metabolites with respect to heterogeneous tissue compositions in 1H-MR spectroscopic volumes

  2012cited by this paper
• Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia

  2011cited by this paper
• Quantitation of magnetic resonance spectroscopy signals: the jMRUI software package

  2009cited by this paper
• An optical coherence tomography (OCT)-based air jet indentation system for measuring the mechanical properties of soft tissues

  2009cited by this paper
• Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study

  2009cited by this paper
• Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study

  2008cited by this paper
• Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia

  2007cited by this paper
• Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans.

  2007cited by this paper
• Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia

  2007cited by this paper
• Grey and white matter differences in brain energy metabolism in first episode schizophrenia: 31P-MRS chemical shift imaging at 4 Tesla.

  2006cited by this paper
• Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia

  2005influential reference
• Basal ganglia high-energy phosphate metabolism in neuroleptic-naive patients with schizophrenia: a 31-phosphorus magnetic resonance spectroscopic study.

  2004cited by this paper
• Focal changes in brain energy and phospholipid metabolism in first-episode schizophrenia

  2004cited by this paper
• The GABA-glutamate connection in schizophrenia: which is the proximate cause?

  2004cited by this paper
• Membrane phospholipid abnormalities of basal ganglia in never-treated schizophrenia: a 31P magnetic resonance spectroscopy study.

  2003cited by this paper
• Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers.

  2002influential reference
• Quantitative 31P spectroscopic imaging of human brain at 4 Tesla: Assessment of gray and white matter differences of phosphocreatine and ATP

  2001cited by this paper
• Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a (31)P chemical shift spectroscopic-imaging study.

  2000cited by this paper
• Reduced phosphodiesters and high-energy phosphates in the frontal lobe of neuroleptic-free schizophrenic patients — a 31P-chemical shift spectroscopic-imaging study☆

  2000cited by this paper
• Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders.

  2000cited by this paper
• Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings--part II.

  2000cited by this paper
• Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings--part I.

  2000cited by this paper
• NMDA receptor hypofunction model of schizophrenia.

  1999cited by this paper
• Development, disease and degeneration in schizophrenia: a unitary pathophysiological model.

  1999cited by this paper
• Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging.

  1998cited by this paper
• The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia.

  1998cited by this paper
• High-energy phosphates in the frontal lobe correlate with Wisconsin Card Sort Test performance in controls, not in schizophrenics: a 31phosphorus magnetic resonance spectroscopic and neuropsychological investigation.

  1998cited by this paper
• Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia.

  1997cited by this paper
• Cocaine and amphetamine preferentially stimulate glutamate release in the limbic system: Studies on the involvement of dopamine

  1997cited by this paper
• Improved method for accurate and efficient quantification of MRS data with use of prior knowledge

  1997cited by this paper
• The Effects of Stress on Central Dopaminergic Neurons: Possible Clinical Implications

  1997cited by this paper
• Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy.

  1997influential reference
• 31P magnetic resonance spectroscopy studies in schizophrenia.

  1996cited by this paper
• An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy.

  1995cited by this paper
• Correlation between left frontal phospholipids and Wisconsin Card Sort Test performance in schizophrenia.

  1995cited by this paper
• Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia.

  1995cited by this paper
• The membrane hypothesis of schizophrenia.

  1994cited by this paper
• Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia.

  1994cited by this paper
• Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study.

  1994cited by this paper
• Structural Organization of Cingulate Cortex: Areas, Neurons, and Somatodendritic Transmitter Receptors

  1993cited by this paper
• Estimation of metabolite concentrations from localized in vivo proton NMR spectra

  1993cited by this paper
• Biochemical considerations in 1H spectroscopy. Glutamate and glutamine; Myo‐inositol and related metabolites

  1991cited by this paper
• Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy.

  1991cited by this paper
• Metabolism and role of glutamate in mammalian brain.

  1990cited by this paper
• 31P nuclear magnetic resonance (NMR) spectroscope of the frontal lobe metabolism in neuroleptic naive first episode psychoses: preliminary studies

  1989cited by this paper
• The positive and negative syndrome scale (PANSS) for schizophrenia.

  1987cited by this paper

• Metabolic Mechanisms in Electroconvulsive Therapy for Schizophrenia: Role, Potential and Future Directions.

  2026cites this paper
• Identification of biomarkers and therapeutic targets of schizophrenia using glutamine metabolism.

  2025cites this paper
• Dysregulation of Glu-GABA and reduction of triglycerides contribute to valproic acid-induced autism model in zebrafish

  2025cites this paper
• Identifying serum lipidomic signatures related to prognosis in first-episode schizophrenia

  2025cites this paper
• Microglial Reactivity in the Prefrontal Cortex in Schizophrenia

  2023cites this paper
• Variability and magnitude of brain glutamate levels in schizophrenia: a meta and mega-analysis

  2023cites this paper
• Dorsolateral Prefrontal Cortex Glutamate/Gamma-Aminobutyric Acid (GABA) Alterations in Clinical High Risk and First-Episode Schizophrenia: A Preliminary 7-T Magnetic Resonance Spectroscopy Imaging Study

  2022cites this paper
• Glutamate and N-Acetylaspartate Alterations Observed in Early Phase Psychosis: A Systematic Review of Proton Magnetic Resonance Spectroscopy Studies.

  2022cites this paper
• The effects of acute dopamine depletion on resting-state functional connectivity in healthy humans.

  2022cites this paper
• On the relationship between GABA+ and glutamate across the brain

  2022cites this paper
• Emerging methods and applications of ultra-high field MR spectroscopic imaging in the human brain.

  2021cites this paper
• Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level

  2021cites this paper
• No balance between glutamate+glutamine and GABA+ in visual or motor cortices of the human brain: A magnetic resonance spectroscopy study

  2021cites this paper
• No balance between glutamate+glutamine and GABA+ in visual and motor cortices of the human brain

  2021cites this paper
• Medial Prefrontal Cortex Glutamate Is Reduced in Schizophrenia and Moderated by Measurement Quality: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies

  2021cites this paper
• Glutamate in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia: A Meta-analysis of 1H-Magnetic Resonance Spectroscopy Studies.

  2020cites this paper
• Attenuated Psychosis Syndrome

  2020cites this paper
• Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms

  2020cites this paper
• Anterior Cingulate Cortex Glutamate Levels Are Related to Response to Initial Antipsychotic Treatment in Drug-Naive First-Episode Schizophrenia Patients

  2020cites this paper
• Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients

  2020cites this paper
• Relationship of auditory electrophysiological responses to magnetic resonance spectroscopy metabolites in Early Phase Psychosis.

  2019cites this paper
• Using proton magnetic resonance spectroscopic imaging to study glutamatergic alterations in patients with schizophrenia: A systematic review.

  2019cites this paper
• Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study.

  2019cites this paper
• Plasma metabolites in first episode psychoses.

  2019cites this paper
• The Role of Docosahexaenoic Acid (DHA) on Cognitive Functions in Psychiatric Disorders

  2019cites this paper
• Towards a theory of functional magnetic resonance spectroscopy (fMRS): A meta-analysis and discussion of using MRS to measure changes in neurotransmitters in real time.

  2018cites this paper
• Comparative Studies of Glutamine Synthetase Levels in the Brains of Patients with Schizophrenia and Mentally Healthy People

  2018cites this paper
• Neurometabolic abnormalities in the associative striatum in antipsychotic-naïve first episode psychosis patients.

  2018cites this paper
• Effect of Bilateral Prefrontal rTMS on Left Prefrontal NAA and Glx Levels in Schizophrenia Patients with Predominant Negative Symptoms: An Exploratory Study.

  2017cites this paper
• Hippocampal metabolism and prefrontal brain structure: A combined 1H-MR spectroscopy, neuropsychological, and voxel-based morphometry (VBM) study.

  2017cites this paper
• Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: A systematic review and meta-analysis.

  2017cites this paper
• Magnetic Resonance Spectroscopy and its Clinical Applications: A Review.

  2017cites this paper
• A review of altered biochemistry in the anterior cingulate cortex of first-episode psychosis

  2017cites this paper
• Disturbed glutathione antioxidative defense is associated with structural brain changes in neuroleptic-naïve fi rst-episode psychosis patients ☆

  2017cites this paper
• Disturbed glutathione antioxidative defense is associated with structural brain changes in neuroleptic-naïve first-episode psychosis patients.

  2017cites this paper
• Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders.

  2017influential citation
• [Comparative study of glutamate dehydrogenase in the brain of patients with schizophrenia and mentally healthy people].

  2017cites this paper
• Environmental enrichment rescues the effects of early life inflammation on markers of synaptic transmission and plasticity.

  2016cites this paper
• How do abnormalities in the brain's spontaneous activity translate into symptoms in schizophrenia? From an overview of resting state activity findings to a proposed spatiotemporal psychopathology.

  2016cites this paper
• Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics

  2016cites this paper
• Dysfunction of the cingulo-opercular network in first-episode medication-naive patients with major depressive disorder.

  2016cites this paper
• Мoзговая изоформа креатинкиназы в лимбической коре мозга в норме и при шизофрении

  2016cites this paper
• [Creatine kinase isoform B distribution in the brain in schizophrenia].

  2016cites this paper
• Neuronal and brain morphological changes in animal models of schizophrenia.

  2016cites this paper
• Synaptic lipids in cortical function and psychiatric disorders

  2015cites this paper
• Clinical Case Reports International

  year unknowncites this paper
• Creatine kinase isoform B distribution in the brain patient with schizophrenia and control cases

  year unknowncites this paper